Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Glioblastoma 7Recurrence 2Prostatic Neoplasms 2Brain Neoplasms 2Astrocytoma 2Optic Nerve Glioma 1Oligodendroglioma 1Metatropic dwarfism 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Gliosarcoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Cilengitide × Clear all
NCT00082875 2013-06-05

Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma

National Cancer Institute (NCI)

Phase 2 Terminated
56 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡